BioMarin Director Barbara Bodem Receives 7,490 Restricted Stock Units

BioMarin Pharmaceutical Inc. director Barbara W. Bodem received 7,490 restricted stock units on June 2, 2026, as reported in this Form 4 filing. The transaction represents an award of equity compensation to the director, with the shares having no purchase price as they are restricted stock units. Following this transaction, Bodem's total holdings in BioMarin common stock increased to 21,045 shares. The filing notes that the restricted stock units were granted on June 2, 2026, and that the price is not applicable for this type of equity award. The filing was signed by attorney-in-fact Tae Sang Yoo on June 4, 2026, and reports the transaction as required under Section 16 of the Securities Exchange Act. This represents standard director compensation through equity awards rather than a market purchase of shares.